Plus Therapeutics (DE:XMP1)
NASDAQ:XMP1
XMP1 Stock Chart & Stats
€1.13
-€0.01(-0.84%)
At close: 4:00 PM EST
€1.13
-€0.01(-0.84%)
Day’s Range― - ―
52-Week Range€4.42 - €28.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.00
Market Cap
€32.41M
Enterprise Value€11.79M
Total Cash (Recent Filing)€3.02M
Total Debt (Recent Filing)€725.00K
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 19, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume78
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.63Price Target Upside2787.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.33
Revenue Forecast (FY)€5.19M
Bulls Say, Bears Say
Bulls Say
Regulatory: Orphan Drug DesignationOrphan designation provides enduring regulatory advantages—market exclusivity, tax credits, and fee reductions—that materially improve the expected economics and development incentives for REYOBIQ across rare CNS indications, strengthening the commercial and regulatory pathway if clinical success follows.
Access To Public Capital Markets MaintainedRestoring Nasdaq compliance preserves Plus Therapeutics’ ability to tap public equity and maintain institutional visibility. For a development-stage biotech dependent on external funding, continued exchange listing materially sustains future financing options and strategic partnerships over the medium term.
Low Leverage & High Gross MarginsModest debt levels reduce short-term solvency pressure while very high gross margins suggest favorable unit economics for the radiotherapeutic platform. Together these durable fundamentals improve financial flexibility and imply attractive product-level profitability once revenues scale.
Bears Say
Persistent Cash BurnSustained, large negative operating and free cash flows create continuous funding needs. Over a multi-month horizon this forces frequent capital raises or dilutive financings, constraining strategic flexibility and increasing execution risk for lengthy clinical development programs.
Very Small, Declining Revenue & Large LossesRevenue remains immaterial and declined materially year-over-year while losses stay very large. This structural mismatch means the cost base is unsupported by sales, prolonging dependence on external capital and delaying any durable path to self-funded operations absent successful approvals.
Historic Equity Instability & Dilution RiskPrior swings into negative equity signal past financing stress and governance reliance on recapitalizations. With authorized shares unchanged post-split, management retains ability to issue equity, heightening durable dilution risk as the company likely must raise capital to fund clinical programs.
Plus Therapeutics News
XMP1 FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was €4.42 and its highest was €28.15 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is €32.41M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 77 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -€0.904 earnings per share for the quarter, missing the consensus estimate of -€0.73 by -€0.174.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.78.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -€0.904 in its last earnings report, missing expectations of -€0.73. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in DE:XMP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.63 (2787.86% Upside)
€32.63 (2787.86% Upside)
Blogger Sentiment
Bullish
DE:XMP1 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.49%
12-Months-Change
Fundamentals
Return on Equity
-198.48%
Trailing 12-Months
Asset Growth
65.20%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
XMP1 Stock 12 Month Forecast
Average Price Target
€32.63
▲(2787.86% Upside)
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Options Prices
Currently, No data available
---